ClinConnect ClinConnect Logo
Search / Trial NCT06090734

Development and Evaluation of 'My Voice': a Randomized Controlled Trial

Launched by DUKE-NUS GRADUATE MEDICAL SCHOOL · Oct 13, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

The clinical trial titled "Development and Evaluation of 'My Voice'" is focused on creating and testing a web-based platform designed to help patients with heart failure and their caregivers. This platform, called 'My Voice', aims to educate users about heart failure, clarify their goals for end-of-life care, and facilitate communication of these goals with their caregivers and healthcare providers. The study is currently looking for participants who are at least 21 years old, have a diagnosis of heart failure, and can read and speak English, Mandarin, or Malay. Caregivers of these patients can also join the study if they are nominated by the patient and meet similar language and contact criteria.

Participants in the trial can expect to engage with the web platform, which will guide them through important conversations about their health and preferences for care at the end of life. The trial is open to both patients and their caregivers, as long as they have a permanent address in Singapore and are easily reachable by phone. This study is an opportunity for individuals to better understand heart failure and make informed decisions about their care, while also ensuring that their loved ones are involved in the conversation.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • - The inclusion criteria for patients are
  • 1. Age ≥ 21 years old
  • 2. Singaporean or Permanent Resident
  • 3. Diagnosed with heart failure
  • 4. Symptoms classified under NYHA class II (with an ejection fraction of less than or equal to 35%), III or IV
  • 5. Intact cognition determined through the Abbreviated Mental Test (AMT) (for pilot testing and main RCT)
  • 6. Ability to speak and read English, Mandarin or Malay
  • 7. Willing to complete a web intervention
  • 8. Easily contactable via mobile phone or landline
  • 9. Have a permanent address in Singapore for at least the next 1 year
  • 10. Not recruited in a previous phase of the study
  • The inclusion criteria for caregivers are
  • 1. Age ≥ 21 years old
  • 2. Nominated as a healthcare spokesperson by the patient or the main decision maker for the patient (for intervention arm only)
  • 3. Ability to speak and read English, Mandarin or Malay
  • 4. Willing to complete a web intervention
  • 5. Easily contactable via mobile phone or landline
  • 6. Have a permanent address in Singapore for at least the next 1 year
  • Exclusion criteria for caregivers are:
  • a) domestic helper

About Duke Nus Graduate Medical School

Duke-NUS Graduate Medical School is a leading biomedical research institution located in Singapore, renowned for its commitment to advancing medical education, research, and healthcare innovation. As a partnership between Duke University in the United States and the National University of Singapore, the school emphasizes a collaborative approach to tackling pressing health challenges through cutting-edge clinical trials and interdisciplinary research. With a focus on translating scientific discoveries into practical applications, Duke-NUS plays a pivotal role in shaping the future of medicine and healthcare in the region and beyond.

Locations

Singapore, , Singapore

Patients applied

0 patients applied

Trial Officials

Chetna Malhotra

Principal Investigator

Duke-NUS Graduate Medical School

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported